Harrow Completes Its Acquisition of Melt Pharmaceuticals

NASHVILLE, Tenn.—Harrow (Nasdaq: HROW), a provider of ophthalmic disease management solutions in North America, announced that it has completed the acquisition of Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. Melt will be fully integrated into Harrow’s operations to ensure a “seamless transition and accelerate progress toward NDA submission, approval, and market launch” of MELT-300, its lead product, the announcement said. Financial terms of the deal were not disclosed.